Domtar (UFS) Surpasses Q2 Earnings & Revenue Estimates
Zacks Investment Research | Jul 27, 2016 10:14PM ET
Domtar Corporation (TO:UFS) reported adjusted income of $38 million or 61 cents per share for the second quarter of 2016 versus $39 million or 61 cents per share in the year-ago quarter. Earnings comprehensively beat the Zacks Consensus Estimate of 19 cents.
GAAP net income was $18 million or 29 cents per share versus $38 million or 60 cents per share in the year-ago quarter. The year-over-year decline in earnings was primarily due to lower revenues.
Sales in the quarter were $1,267 million versus $1,310 million in the year-ago quarter. Revenues however beat the Zacks Consensus Estimate of $1,258 million.
Operating income for the reported quarter came in at $39 million, compared to $18 million in the first quarter of 2016. The increase in operating income was driven by lower impairment of property, plant & equipment charge, increased average selling prices and fall in operational costs.
Segment Performance
Pulp and Paper: Sales from this segment were $1,054 million versus $1,110 million in the year-ago period. Operating income came in at $35 million versus $55 million in the year-ago quarter. Paper inventories decreased by 37,000 tons, while pulp inventories decreased by 16,000 metric tons.
The conversion of the Ashdown paper machine to fluff pulp is still in progress and operations are scheduled to begin in the third quarter. Through such endeavors, the company is actively pursuing growth opportunities to capitalize on its existing strengths and core competencies.
Personal Care: Sales were $228 million versus $216 million in the year-earlier quarter, while operating income was $15 million versus $17 million in the year-ago quarter.
Acquisitions
During the quarter, Domtar acquired the assets of Butterfly Health Inc. for an undisclosed amount. The strategic acquisition extends the Personal Care segment of Domtar with complementary products. The company’s Personal Care segment manufactures and sells a wide range of incontinence solutions for adults, children and infants under leading brands like ATTENDS, ATTENDS DISCREET and COMFEES. This acquisition will facilitate the company to strengthen its position in the market. Domtar is expected to leverage its global footprint to extend its presence in additional healthcare markets, with a focus on Europe.
Balance Sheet
Cash and cash equivalents totaled $111 million as of Jun 30, 2016. Long-term debt was $1,237 million at quarter end. Cash flow from operating activities totaled $118 million and capital expenditures were $119 million. Domtar’s net debt-to-total capitalization ratio was 30% as of June 30, 2016.
The company did not have any shares repurchases during the quarter. At the end of the quarter, the company had 62.7 million shares outstanding.
DOMTAR CORP Price, Consensus and EPS Surprise/h3
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.